Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 765845 in Healthy Volunteers
NCT06139315Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 765845 in acute myocardial infarction (AMI) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with treatment-emergent adverse events up to 73 days. Started Jun 2022; status: completed.
02
Drugs
BI 765845
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT06139315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139315.